Tags: biotech

Biotech workforce continued to expand in Mass. last year, report says

Biotech workforce continued to expand in Mass. last year, report says

But as venture outlays fall, a recent spurt of layoffs has clouded outlook By Robert Weisman Globe Staff Massachusetts continued to expand its biopharma workforce in research labs and manufacturing plantslast year even as venture capital investment dwindled and fewer biotech companies went public. Overall employment in the sector — a bellwether of the state’s […]

Read more
President Biden wants to build a ‘bioeconomy.’ Here’s what that means for Boston.

President Biden wants to build a ‘bioeconomy.’ Here’s what that means for Boston.

President Joe Biden is infusing billions of dollars into a new, biotech-focused initiative, and it’s likely to have immediate ramifications for New England. Boston has long been a hotbed for pharmaceuticals in addition to upstart biotechs. But the White House is expanding the definition of what a “bioeconomy” could be, looking beyond drugmaking to other applications of […]

Read more

Ipsen Pharmaceuticals moving R&D to Cambridge

France-based pharmaceutical company Ipsen recently announced that it will be relocating its research and development facility from Milford to East Cambridge. Following the trend of big biotech and pharma companies planning the move to Cambridge, Ipsen signed a long-term lease for 62,600 square feet of lab and office space at 650 Kendall Street in Kendall Square. […]

Read more

An Update on Cambridge Construction

There are currently 2.5 million square feet under construction in the city of Cambridge. From Central Square to East Cambridge, commercial real estate development is thriving. A great deal of this construction consists of lab space for tech and pharmaceutical companies. One reason for this is the Commonwealth is looking to take advantage of the talent […]

Read more

Local Biotech Company Goes Public

Epizyme Inc, a Cambridge-based cancer drug company, commenced public trading last Friday. The biotech listed its initial public offering at $15 a share on the Nasdaq, under the ticker symbol “EPZM.” The rapidly-growing oncology company is offering 5.1 million shares, with the IPO expected to raise $88.8 million if all shares are sold. While only […]

Read more

Compare